Abstract
AbstractClinical experience with antidementia drugs in dementia in Parkinson's disease (PDD) is still limited and a lack of diagnostic criteria and specific screening tests further complicates clinical decision making. Here, the authors discuss the results of a postal survey sent to PD clinicians in the UK to assess their methods of diagnosis and use of antidementia drugs in PDD patients. Copyright © 2007 Wiley Interface Ltd
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call